REVA Medical to Present at UBS Global Life Sciences Conference
September 13 2011 - 8:00PM
REVA Medical, Inc. (ASX:RVA) ("REVA" or the "Company") is pleased
to announce that Chairman and CEO, Bob Stockman, is scheduled to
make a presentation at the UBS Global Life Sciences Conference at
7:30 a.m. EDT on Tuesday, September 20, 2011. The conference is
being held September 19-21, 2011 at the Grand Hyatt New York Hotel
in New York City.
Mr. Stockman will present an overview of REVA and its
proprietary ReZolve™ bioresorbable stent to institutional
investors. A copy of the presentation materials will be available
on the Company's website at www.revamedical.com shortly after the
presentation.
About REVA
REVA is a development stage medical device company incorporated
in Delaware, USA, that is focused on the development and eventual
commercialisation of its proprietary, bioresorbable stent products.
REVA's lead product, the ReZolve™ stent, combines REVA's
proprietary stent design with a proprietary polymer that is
metabolised and cleared from the body. The ReZolve stent is
designed to offer full x-ray visibility, clinically relevant sizing
and a controlled and safe resorption rate. In addition, by early
encapsulation of the stent in the artery tissue coupled with the
loss of stent structure over time, the ReZolve stent may reduce the
incidence of late forming blood clots, or thrombosis, a rare but
serious problem associated with drug-eluting metal stents currently
on the market. REVA is in the process of finalising the design of
its ReZolve stent and will require regulatory approval before it
can begin selling the ReZolve stent.
The REVA Medical, Inc. logo is available at
http://www.globenewswire.com/newsroom/prs/?pkgid=8505
CONTACT: Investor and Media Enquiries:
Cheryl Liberatore
Director, Investor Relations and Marketing
REVA Medical, Inc.
+1 858-966-3045
Reva Medical (ASX:RVA)
Historical Stock Chart
From Apr 2024 to May 2024
Reva Medical (ASX:RVA)
Historical Stock Chart
From May 2023 to May 2024